A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands
CONCLUSIONS: Implementing Oncotype DX testing in this population can prevent unnecessary overtreatment, reducing clinical and economic burden on the patient and Dutch healthcare system.PMID:38436289 | DOI:10.1080/13696998.2024.2324612 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 4, 2024 Category: Health Management Authors: Martijn J H G Simons Peter M Machielsen Jelle A Spoorendonk Tim Ignacio Pieter B Drost Tim Jacobs Felix E deJongh Source Type: research
Placebo responses vary by route of administration in migraine prevention trials. What does this mean?
J Med Econ. 2024 Mar 1:1-5. doi: 10.1080/13696998.2024.2323900. Online ahead of print.NO ABSTRACTPMID:38425286 | DOI:10.1080/13696998.2024.2323900 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - March 1, 2024 Category: Health Management Authors: Christina I Deligianni Paolo Martelletti Dimos D Mitsikostas Source Type: research
Post-approval indications and clinical trials for cardiovascular drugs and some implications of the US inflation reduction act
ConclusionsPost-approval FDA indication approvals and clinical trial starts and primary completion dates often occurred after or near new DPNP selection and MFP implementation dates. This has economic consequences for future investment incentives. Post-approval trials for small molecules, longer-duration trials, and larger-enrollment trials, and post-approval indications focused on limited patient populations and older patients could face particular economic challenges.PMID:38419523 | DOI:10.1080/13696998.2024.2323903 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 29, 2024 Category: Health Management Authors: Henry Grabowski Genia Long Source Type: research
Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia
Conclusions: CV cost-offsets and drug acquisition considerations may make semaglutide a favorable use of resources for Saudi budget planners and decision-makers. These results were robust to assumptions regarding the list price of tirzepatide.PMID:38420695 | DOI:10.1080/13696998.2024.2319458 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 29, 2024 Category: Health Management Authors: Hussain A Al-Omar Hind S Almodaimegh Abubker Omaer Lamya M Alzubaidi Bandar Al-Harbi Ibtisam Al-Harbi Mohamed Hassan Abdulmohsen Abanumay Omar Akhtar Source Type: research
Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States
Conclusion: This real-world study demonstrated a significant economic burden in mCSPC patients, and a propensity to use ADT monotherapy in clinical practice despite the availability and guideline recommendations of advanced life-prolonging therapies.PMID:38420699 | DOI:10.1080/13696998.2024.2323901 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 29, 2024 Category: Health Management Authors: Deborah R Kaye Ibrahim Khilfeh Erik Muser Laura Morrison Frederic Kinkead Patrick Lefebvre Dominic Pilon Daniel George Source Type: research
Post-approval indications and clinical trials for cardiovascular drugs and some implications of the US inflation reduction act
ConclusionsPost-approval FDA indication approvals and clinical trial starts and primary completion dates often occurred after or near new DPNP selection and MFP implementation dates. This has economic consequences for future investment incentives. Post-approval trials for small molecules, longer-duration trials, and larger-enrollment trials, and post-approval indications focused on limited patient populations and older patients could face particular economic challenges.PMID:38419523 | DOI:10.1080/13696998.2024.2323903 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 29, 2024 Category: Health Management Authors: Henry Grabowski Genia Long Source Type: research
Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia
Conclusions: CV cost-offsets and drug acquisition considerations may make semaglutide a favorable use of resources for Saudi budget planners and decision-makers. These results were robust to assumptions regarding the list price of tirzepatide.PMID:38420695 | DOI:10.1080/13696998.2024.2319458 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 29, 2024 Category: Health Management Authors: Hussain A Al-Omar Hind S Almodaimegh Abubker Omaer Lamya M Alzubaidi Bandar Al-Harbi Ibtisam Al-Harbi Mohamed Hassan Abdulmohsen Abanumay Omar Akhtar Source Type: research
Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States
Conclusion: This real-world study demonstrated a significant economic burden in mCSPC patients, and a propensity to use ADT monotherapy in clinical practice despite the availability and guideline recommendations of advanced life-prolonging therapies.PMID:38420699 | DOI:10.1080/13696998.2024.2323901 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - February 29, 2024 Category: Health Management Authors: Deborah R Kaye Ibrahim Khilfeh Erik Muser Laura Morrison Frederic Kinkead Patrick Lefebvre Dominic Pilon Daniel George Source Type: research
